Clinical trial
A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis Suppurativa
NCT05348681 is registered in ClinicalTrials.gov with Aristea Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis Suppurativa
- Lead sponsor
- Aristea Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 18, 2022
- Completion date
- February 28, 2023
- Enrollment
- 25 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.